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Background: Using SRTR/UNOS data, it has previously been shown that increased liver transplant
centre volume improves graft and patient survival. In the current era of health care reform and pay for
performance, the effects of centre volume on quality, utilization and cost are unknown.
Methods: Using the UHC database (2009–2010), 63 liver transplant centres were identified that were
organized into tertiles based on annual centre case volume and stratified by severity of illness (SOI).
Utilization endpoints included hospital and intensive care unit (ICU) length of stay (LOS), cost and
in-hospital mortality.
Results: In all, 5130 transplants were identified. Mortality was improved at high volume centres (HVC) vs.
low volume centres (LVC), 2.9 vs. 3.4%, respectively. HVC had a lower median LOS than LVC (9 vs. 10
days, P < 0.0001), shorter median ICU stay than LVC and medium volume centres (MVC) (2 vs. 3 and 3
days, respectively, P < 0.0001) and lower direct costs than LVC and MVC ($90 946 vs. $98 055 and
$101 014, respectively, P < 0.0001); this effect persisted when adjusted for severity of illness.
Conclusions: This UHC-based cohort shows that increased centre volume results in improved long-
term post-liver transplant outcomes and more efficient use of hospital resources thereby lowering the
cost. A better understanding of these mechanisms can lead to informed decisions and optimization of the
pay for performance model in liver transplantation.
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Introduction
Liver transplantation remains a scarce resource with increasing
demand, continued waiting list mortality and no increase in avail-
able organs.1,2 Recent changes in organ allocation in the past
decade, such as the introduction of the model of end-stage liver
disease (MELD) score, have made strides at decreasing waiting list
mortality and, in certain situations, decreasing waiting list times
for transplant. However, this has come at a cost as this has resulted
in an increased severity of patients typically being transplanted
(i.e. higher MELD) and thus increased post-operative rates of
complication and resource utilization.3,4 The overall improvement
in patient survival and transplant outcomes has come with a
trade-off of significantly higher costs and questions about the
cost-effective of liver transplantation.5–7
With the advent of pending health care reform and pay
for performance measures, the transplantation community can
expect an increase in patient volume and declining reimburse-
ment.8,9 Public and private payers will be increasingly interested in
cost-containment strategies and monitoring outcomes based on
the cost-effectiveness of the procedure and the ability of the pro-
viders and their institutions providing the care.7,10,11
There has been significant work to optimize the liver transplan-
tation allocation process. Many previous studies have studied the
effects of MELD and donor characteristics, such as the donor risk
index (DRI) on transplant outcomes such as length of stay (LOS),
ICU utilization, patient/graft survival and cost.3,6,12–16 To that end,
the effect of the transplant centre volume on liver transplantation
was published, demonstrating that higher volume centres were
able to show increased patient and allograft survival with higher
DRI organs.17 Volume has been reported in the literature with
varying effects on transplant outcome noted.10,18–21 Given the
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variability in the literature, a nationwide database that captures
peri-operative cost data to evaluate volume effects was used.
As the health care industry experiences further cost-cutting
measures and demands from external stakeholders to improve
quality, it is imperative that work is undertaken to better under-
stand what variables influence the cost of the care that is provided.
Methods
To develop this cohort, the UHC CDB/RM database was utilized
to identify 63 transplant centres nationwide. Between 2009 and
2010, 5130 liver transplants were identified. This represents
approximately 50% of the total liver transplants performed in the
US during those 2 years when compared with available data from
the Organ Procurement and Transplantation Network (OPTN).
Utilization endpoints included length of stay (LOS) and direct
cost from the day of the transplant until discharge, ICU days and
severity of illness (SOI). The SOI is an AHRQ-validated risk strati-
fication tool that categorizes a patient as Minor, Moderate, Major
or Extreme. UHC generates this value at the time of admission
using a formulating incorporate the patients All Patient Refined
Diagnosis Group (APR-DRG) Grouper and the contribution of
their underlying comorbidities. Both LOS and direct costs were
addressed from the day of transplant forward in order to account
for prolonged pre-transplant hospitalizations that were variable
across the cohort and to provide a more accurate analysis of a
hospitals ability to care for the patient post-transplant. To address
the potential differences in pre- and post-transplant phase costs,
the total direct cost observed for transplant patient hospitalization
was divided by the total LOS days to create an estimate of the
direct cost per day.
We employed a similar technique as previously published to
analyse transplant centre volume.17 Transplant centres were
ranked in order of annual case volumes by year. Transplant centres
with fewer than five transplants per year were excluded. All obser-
vations were divided into tertiles and categorized into the follow-
ing volume groups: High Volume Centres (HVC; upper one-third
of observations), Middle Volume Centres (MVC; middle one-
third of observations) and Low Volume Centres (LVC; lower one-
third of observations). Because centre-specific procedure volumes
varied from year to year, centre rank and subsequently tertile
group designation were re-calculated for each year studied (See
Table 1).22,23
Categorical values were expressed in percentages and tested
using the c2 test. Continuous variables were expressed as means
or medians and tested using non-parametric analyses. Statistical
analyses were performed using JMP 9 Pro (SAS Institute, Cary,
NC, USA).
UHC is an alliance of the nation’s leading non-profit academic
medical centres with 116 academic medical centres and 261 affili-
ated hospital members through its renowned programmes.
UHC’s membership includes more than 90% of the non-profit
academic medical centres in the United States. The data within the
UHC system are provided by the participating member medical
centres. The data provided are demographic and ICD-9 diagnosis
and procedure data. The member institutions provide charges for
each patient encounter in the database. The charge data are then
converted to a cost estimate using patient-level Medicare cost to
charge ratios. UHC then employs Federally reported area wage
indexes to normalize regional labour cost variation.
Results
In all, 5130 liver transplants from 63 academic transplant centres
were analysed. The analysis was done first by comparing overall
centre volume tertile characteristics and the distribution of
patient severity types (Table 2), and then subsequently stratified
by severity of illness (SOI). See Table 3 for a summary of the
overall centre volume outcome measures and Table 4 for details
regarding the univariate analysis of the cohort by SOI.
The in-hospital mortality between the volume tertiles demon-
strated a significant improvement of 3.4% to 2.9% between low
and high volume centres, respectively. When the centres were
stratified by SOI, there was a significant improvement in mortality
noted for HVCwith extreme cases, 6.5% compared with 8.9% and
8.5% for MVC and LVC, respectively (P < 0.0001). It was noted
Table 1 Volume tertile case ranges, 2009–2010
Tertiles Case range Cases Centres
2009
Low volume centre 11–47 864 38
Medium volume centre 48–75 819 14
High volume centre >76 942 11
Totals 2625 cases 63 centres
2010
Low volume centre 13–43 801 34
Medium volume centre 44–70 864 17
High volume centre >71 840 11
Totals 2505 cases 62 Centers
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that with major cases, LVC had a slight improvement in mortality,
2.3%, compared with HVC and MVC with 3.1% and 2.9%,
respectively (P = 0.017).
Median overall LOS between high and low volume centres was
noted to be 9 and 10, respectively (P < 0.0001).When separated by
severity of illness, significant differences were found across all SOI
categories with more profound differences between LVC and HVC
for Major and Extreme cases. Specifically, Major cases saw a dif-
ference in LOS at LVC of 11 vs. 9 days at HVC (P < 0.0001) and
Extreme cases were noted to have a LOS of 17 days at LVC and 13
days at HVC (P < 0.0001).
When looking at ICU utilization, measured in median days,
there was a significant overall reduction for HVC, 2 days com-
pared with 3 days for both MVC and LVC (P < 0.0001). When
stratified by SOI, the effect persisted with decreasing ICU utiliza-
tion from LVC to HVC’s with the profound difference with
Extreme cases, where there was a 3-day decrease in the ICU utili-
zation at HVC as opposed to LVC.
The median direct cost of the inpatient admission from the
time of transplant was significantly different between the three
tertiles with median costs of $90 946 for HVC, $101 104 for MVC
and $98 055 for LVC (P < 0.0001).When stratified by SOI, the cost
differences varied slightly with significant direct cost improve-
ments from LVC to HVC for Minor, Moderate and Major cases.
There was a $14 700 improvement in the cost for Major cases at
HVC vs. LVC. At the Extreme cases level, there was a greater than
$10 000 difference in cost between HVC and LVC; however, the
difference failed to reach significance.
Discussion
The results of the present study using the UHC Database have
demonstrated a relationship between transplant centre volume
and measurements of resource utilization in liver transplantation.
As reported previously, centre volume has implications in the use
of extended criteria livers and now seems to be a potential factor
in the efficient use of hospital resources based on patient illness
severity.17 When discussing cost-effectiveness and resource utili-
zation, it is always important to keep patient safety and survival as
the priority before addressing issues surrounding cost. Interest-
Table 2 Distribution of severity of illness patients between centre volume tertiles
Severity of illness Centre volume tertiles
Low volume centre Medium volume centre High volume centre
Minor 133 (8.0%) 160 (9.5%) 143 (8.0%)
Moderate 650 (39.0%) 715 (42.5%) 719 (40.3%)
Major 564 (33.9%) 522 (31.0%) 551 (30.9%)
Extreme 318 (19.1%) 286 (17.0%) 369 (20.7%)
Table 3 Summary table of demographic and overall outcome measures by centre volume tertile
Low volume
centre
Medium volume
centre
High volume
centre
Median age (range) 56 (18–78) 56 (18–75) 57 (18–81)
Gender
Males (per cent) 1 138 (32.8%) 1 153 (33.2%) 1 181 (34.0%)
Females (per cent) 527 (31.7%) 530 (32.0%) 601 (36.3%)
Race
White (per cent) 1 151 (32.0%) 1 221 (34.0%) 1 223 (34.0%)
Black (per cent) 165 (33.7%) 186 (38.0%) 138 (28.2%)
Hispanic (per cent) 154 (37.7%) 95 (23.2%) 160 (39.1%)
Asian (per cent) 71 (32.9%) 71 (32.9%) 74 (34.3%)
Other (per cent) 124 (29.5%) 110 (26.1%) 187 (44.4%)
P-values
Mortality (%) 3.4 3.3 2.9 0.004*
Transplant to discharge length of stay
(interquartile range)
10 (7–16) 10 (7–15) 9 (7–13) <0.0001*
ICU length of stay (interquartile range) 3 (2–8) 3 (2–6) 2 (1–6) <0.0001*
Direct cost of transplant to discharge
length of stay (interquartile range)
98 055 (74 287–129 969) 101 014 (79 871–141 208) 90 946 (74 274–122 716) <0.0001*
*P < 0.05 considered statistically significant.
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ingly enough, the most impressive patient survival benefit we
found occurred with the most extreme severity cases with HVC
providing greater than a 2% improvement in mortality. With
regards to utilization, HVC demonstrated significant efficiencies
in care for the sickest of patients; however, this benefit appeared to
wane for less severe patients. This correlates with previous find-
ings that HVC have superior patient and graft survival when
employing higher DRI allografts. Although we did not address
MELD or DRI in this study, the UHC SOI score is an AHRQ
risk-adjusted marker for patient severity and is calculated for each
patient based on his or her diagnosis and/or procedure. Although
not addressed here, a strong correlation was noted between the
UHC SOI score and the MELD and it was felt it may be a good
surrogate for MELD and patient risk stratification in the future.
We plan to address this in future research.
An important aspect of this study was the evaluation of the cost
post-transplant, in addition to the cost of the entire LOS. The
correlation between higher volume and lower cost of care was
stronger when analysed from the date of transplant to discharge.
Pre-transplant LOS variability is likely difficult to address in the
context of volume, as is resource overall resource utilization. It is
hard to discern if a transplant centre’s experience would portend
higher quality and more cost-effective care pre-transplant as addi-
tional variables such as transplant region, waiting list status and
diagnosis would likely cloud the picture. In this study, it is felt that
the volume status of the centre is most critical around the imme-
diate peri-operative timeframe through to the discharge of the
patient. An additional area that will be considered in the future
is readmission rates, particularly in the context of transplant-
specific variables and centre volume. This is an important
outcome measure that is important to consider in the context of
LOS and cost savings. Peri-operative improvements in LOS, ICU
utilization and cost may be negated by increases in readmission
rates. In addition, taking into account the costs of readmission as
well as any post-operative costs represents a more accurate repre-
sentation of the total cost of a liver transplant.
As we highlighted earlier, donor and recipient variables are of
critical importance to optimise patient and graft success post-
transplant. The characterisation of recipient variables using
MELD has been instrumental in making improvements to alloca-
tion algorithms and helping to boost transplant outcomes. The
use of the DRI has been helpful in understanding donor variables
and how they affect patient care, although this has not translated
into the allocation system directly.24 However, the new paradigms
Table 4 Univariate comparisons of variables stratified by volume tertiles
Low volume centre Medium volume centre High volume centre P-value
Mortality (%)
Minor 1.2 0.0 0.7 0.021*
Moderate 2.6 1.5 1.3 <0.0001*
Major 2.3 2.9 3.1 0.017*
Extreme 8.5 8.9 6.5 <0.0001*
Transplant to discharge
length of stay
(interquartile range)
Minor 8 (6–11) 8 (6–11) 8 (6–9) 0.0018*
Moderate 8 (7–12) 8 (7–11) 8 (6–11) 0.0104*
Major 11 (8–16) 10 (7–16) 9 (7–13) <0.0001*
Extreme 17 (11–27) 16 (11–27) 13 (9–24) <0.0001*
ICU length of stay
(interquartile range)
Minor 3 (1.5–4) 3 (2–4) 2 (1–3) <0.0001*
Moderate 3 (2–4.3) 2 (1–4) 2 (1–4) <0.0001*
Major 4 (2–8) 3 (2–6) 2 (1–5) <0.0001*
Extreme 10 (4–20.3) 8 (4–15.3) 7 (3–17) 0.0145*
Direct cost of transplant to
discharge length of stay
(interquartile range)
Minor 93 179 (74 957–120 840) 102 571 (81 145–152 057) 88 835 (72 530–118 457) 0.0274*
Moderate 93 369 (72 310–121 448) 103 770 (81 721–140 415) 90 624 (74 570–117 520) <0.0001*
Major 102 399 (78 456–130 240) 95 325 (78 163–126 796) 87 693 (75 061–117 906) <0.0001*
Extreme 110 851 (73 344–165 804) 105 817 (78 133–157 136) 98 960 (71 485–147 775) 0.1646
*P < 0.05 considered statistically significant.
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of health care reform and pay-for-performance threaten beneficial
yet costly interventions.8,9,14,15,25 In this study, the correlations
between LOS and ICU utilization as markers for possible liver
transplant quality and efficiency of care are highlighted. LOS has
been described previously as a surrogate for resource utilization in
liver transplantation.26 Several previous studies have demon-
strated that increasing MELD does result in increased cost and
LOS, interestingly enough these same studies highlighted that
hospitals that treated the highest MELD patients had a lower
overall LOS indicating a possible learning curve.14,27,28 Similar
results where see in the present study and that hospitals seeing
sicker patients, in this case as indicated by UHC severity of illness,
were more efficient in taking care of these patients post-
transplant. This effect appeared to reside with HVC, although we
would want to correlate this effect with an analysis using the
MELD and DRI scores and controlling for any differences in the
distribution of more severe patients to certain hospitals and/or
UNOS transplant regions. In addition, it would be interesting to
see what types of patients were being transplanted at the LVC and
MVC with regards to diagnosis, MELD exemptions and compare
them in context to the pre-transplant LOS.
It is important to point out several limitations of this study.
First, the UHC database is not a transplant database and contains
administrative data pertaining only to the particular admission of
interest. This may result in data entry errors and the database fails
to capture approximately 50% of annual liver transplants per-
formed. In addition, given the absence of roughly 50% of the US
transplant centres, the true range of case volume is likely not
represented in its entirety. For example, the max annual case
volume reported by a centre in this study is 165 cases in spite of
there being several centres not included in the UHC database that
perform over 200 transplants per year. Second, the database only
contains academic medical centre data. However, we feel that the
majority of liver transplants only occur at academic medical
centres. Third, the direct cost calculation in UHC utilizes Medi-
care cost–charge ratios as well as geographical labour–rate varia-
tions. It is based on hospital-reported charge data and may
contain inherent flaws. However, given the consistent manner in
which the database generates cost data, it is felt it is a strong
database for comparing relative costs between institutions within
the UHC system. Finally, we focused primarily on the post-
transplant LOS both overall and for ICU utilization. That may
have missed some critical information as it relates to the various
volume centres. We plan to include data on the entire LOS in
future work to ensure we address the entire admission as it relates
to cost and resource utilization. Within UHC, it is difficult to
identify when the patient entered the ICU and therefore to corre-
late it with the timing of the transplant.Work is ongoing in being
able to identify this in the future to be sure that the post-
transplant vs. overall admission ICU utilization can be framed
accurately. There are likely a number of patients that were admit-
ted to ICU before the transplant and required a tremendous
amount of hospital resources prior to their transplant.
There are many potential reasons for the benefits seen at HVC,
such as surgeon experience, transplant team experience and
resource availability. Regardless, the results of this study require
further investigation as they imply the possibility of being able to
optimize health care resource utilization while potentially
improving patient and graft survival. Although recommendations
for changes to the allocation system to incorporate centre vari-
ables is out of the scope of this study, these data do suggest that
there is value in assessing centres by their ability to optimally
perform and manage certain types of transplants based on avail-
able allografts.We recognize that these data require validation and
more detailed analysis; however, centre volume appears to play a
large role in outcomes of liver transplantation.
The need for the field of surgery to develop definable and
applicable measures of quality and safety are critical for patient
referrals and reimbursement. Surrogate measures of health care
outcomes have been debated in the literature and have been
accused of painting an incomplete picture of the success of a given
treatment or care modality.29 Regardless, addressing liver trans-
plantation both with regards to patient quality, safety and cost will
be of the utmost importance if the modality is to remain a viable
treatment option for patients.
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